Grant for Investigator-Initiated Clinical Trial

The StratCan Grant for Investigator-Initiated Clinical Trial is a one year grant to support the planning and implementation of an investigator-initiated clinical trial.

About the Grant

Investigator-initiated research involving investigational drugs is key to developing novel therapies against cancer. 

The award can cover a broad variety of different activities aiming at enabling an investigator-initiated clinical trial in cancer. Although the support is not intended to cover the total cost of the trial, the grant should support efforts to bring it to the stage where the project is competitive enough to attract funding from other academic or non-academic funding agencies or from industry (The project should not be supported by non-academic funding at the time of application). The research should be conducted at Karolinska Institutet.

Clinical Trial Grant 2014

Two StratCan Grants for Investigator-Initiated Clinical Trial were awarded in 2014, one to Petter Höglund and one to Theodoros Foukakis.

Professor

Petter Höglund

Phone: +46-(0)8-585 801 74
Organizational unit: Unit for Hematology
E-mail: Petter.Hoglund@ki.se

Petter Höglund is active at the Department of Medicine, Huddinge and the project is entitled "Acid stripping of platelet HLA before transfusion: A first clinical trial to test efficiency and safety in haematological cancer patients“.

Associated

Theodoros Foukakis

Organizational unit: Research Group Bergh, Jonas
E-mail: Theodoros.Foukakis@ki.se

Theodoros Foukakis is active at the Department of Oncology-Pathology and the project is entitled "CLinical IMpact of Breast Cancer Biomarker HETerogeneity assessed by Single-Cell In Situ Assays - CLIMBBHET"

(Announcement for StratCan Grant for Investigator-initiated Clinical Trial 2014)

Clinical Trial Grant 2012

Associated

Jeanette Lundin

Organizational unit: Research Group Mellstedt, Håkan
E-mail: Jeanette.Lundin@ki.se

Adjunct professor

Anders Österborg

E-mail: Anders.Osterborg@ki.se

Jeanette Lundin and Anders Österborg are both at the Department of Oncology-Pathology and the project is entitled "Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL).